{"id":"clidanac","rwe":[{"pmid":"6334337","year":"1984","title":"The effect of clidanac, a potent anti-inflammatory drug, on mitochondrial respiration: a consideration on the uncoupling activity of optical enantiomers.","finding":"","journal":"Research communications in chemical pathology and pharmacology","studyType":"Clinical Study"},{"pmid":"6714852","year":"1984","title":"[The effects of various drugs on the binding site of bilirubin in serum albumin].","finding":"","journal":"Nihon yakurigaku zasshi. Folia pharmacologica Japonica","studyType":"Clinical Study"},{"pmid":"6133820","year":"1983","title":"[Influence of indomethacin and clidanac on the blood pressure lowering effect of beta-blockers].","finding":"","journal":"Nihon yakurigaku zasshi. Folia pharmacologica Japonica","studyType":"Clinical Study"},{"pmid":"6118407","year":"1981","title":"Optical isomerization of R(-)-clidanac to the biologically active S(+)-isomer in guinea-pigs.","finding":"","journal":"The Journal of pharmacy and pharmacology","studyType":"Clinical Study"},{"pmid":"6114148","year":"1981","title":"Inhibition of prostaglandin biosynthesis by clidanac and related compounds: structural and conformational requirements for PG synthetase inhibition.","finding":"","journal":"The Journal of pharmacy and pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"clidanac","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"indanal","offLabel":[],"synonyms":["TAI-284","TAI 284","clidanac","indanal"],"timeline":[],"approvals":[],"brandName":"Indanal","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"clidanac","explanation":"Think of it like a key fitting into a lock. Indanal is like the key that blocks the action of a specific enzyme, which is like the lock. This helps to restore balance to the body's natural processes and can help to treat certain conditions.","oneSentence":"Indanal works by inhibiting a specific enzyme or pathway to produce its therapeutic effect.","technicalDetail":"Indanal is a clidanac that acts as a competitive inhibitor of a specific enzyme, thereby reducing its activity and altering the downstream signaling pathways."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/675","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CLIDANAC","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:09:53.314486","biosimilars":[],"competitors":[],"genericName":"clidanac","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"UA6HM01WAK","CHEBI":"CHEBI:31411","INN_ID":"4357","UMLSCUI":"C0055876","ChEMBL_ID":"CHEMBL130393","KEGG_DRUG":"D01330","PUBCHEM_CID":"120108","MESH_SUPPLEMENTAL_RECORD_UI":"C059095"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":5,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1984 Sep","pmid":"6334337","title":"The effect of clidanac, a potent anti-inflammatory drug, on mitochondrial respiration: a consideration on the uncoupling activity of optical enantiomers.","journal":"Research communications in chemical pathology and pharmacology"},{"date":"1984 Jan","pmid":"6714852","title":"[The effects of various drugs on the binding site of bilirubin in serum albumin].","journal":"Nihon yakurigaku zasshi. Folia pharmacologica Japonica"},{"date":"1983 Jan","pmid":"6133820","title":"[Influence of indomethacin and clidanac on the blood pressure lowering effect of beta-blockers].","journal":"Nihon yakurigaku zasshi. Folia pharmacologica Japonica"},{"date":"1981 Nov","pmid":"6118407","title":"Optical isomerization of R(-)-clidanac to the biologically active S(+)-isomer in guinea-pigs.","journal":"The Journal of pharmacy and pharmacology"},{"date":"1981 Jan","pmid":"6114148","title":"Inhibition of prostaglandin biosynthesis by clidanac and related compounds: structural and conformational requirements for PG synthetase inhibition.","journal":"The Journal of pharmacy and pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Indanal (CLIDANAC) is a small molecule drug in the clidanac class, but specific details about its target, FDA approval status, and approved indications are not available. As a clidanac, it is a type of medication that works by inhibiting a specific enzyme or pathway. The commercial status of Indanal is unclear, and it is unknown whether it is patented or available as a generic. Further research is needed to determine its safety profile and potential side effects. Overall, Indanal is a relatively unknown medication with limited information available.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}